Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis-Reference-Cited by-同舟云学术

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

Published:2019-03-07 Issue:10 Volume:380 Page:981-983
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Bachelez Hervé¹,Choon Siew-Eng²,Marrakchi Slaheddine³,Burden A. David⁴,Tsai Tsen-Fang⁵,Morita Akimichi⁶,Turki Hamida³,Hall David B.⁷,Shear Michael⁸,Baum Patrick⁸,Padula Steven J.⁹,Thoma Christian⁸

Affiliation:

1. Sorbonne Paris Cité Université Paris Diderot, Paris, France

2. Monash University Malaysia, Johor Bahru, Malaysia

3. Hedi Chaker University Hospital, Sfax, Tunisia

4. University of Glasgow, Glasgow, United Kingdom

5. National Taiwan University, Taipei, Taiwan

6. Nagoya City University, Nagoya, Japan

7. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

8. Boehringer Ingelheim International, Biberach, Germany

9. Boehringer Ingelheim International, Ingelheim, Germany

Funder

Boehringer Ingelheim

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc1811317

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with biologics of patients with inflammatory joint diseases;Pharmacia;2024-09-05

2. Innovations in Psoriasis;Dermatologic Clinics;2024-09

3. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search;Dermatology and Therapy;2024-08-01

4. Generalized pustular psoriasis successfully treated with spesolimab in the setting of metastatic colon cancer;JAAD Case Reports;2024-08

5. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval;Frontiers in Immunology;2024-07-22